Pan-AMPK activation · Small molecule
Evidence gap: Route-specific human PK and absolute bioavailability are not established in the imported material.
Open in the interactive library →Compare with other compounds →
Human oral administration and exposure are documented for the studied O304 formulation.
Context: 65 adults with type 2 diabetes taking metformin.
Limitations: No retail-capsule equivalence, long-term safety, or SLU sequencing benefit is established.
Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.
Context: Human · 65 adults with type 2 diabetes on metformin · O304 oral suspension
Human study regimen: Amount: 1,000 mg; Frequency: Daily; Duration: 28 days; Route: Oral; Species: Human; Population: 65 adults with type 2 diabetes on metformin; Formulation: O304 oral suspension
Limitations: Do not infer retail ATX-304 capsule equivalence, long-term safety or benefit after SLU-PP-332.
Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.
Context: Attributed research context; population or formulation not fully specified.
Attributed proposal / anecdote: Route: Oral; Sequence: After a proposed SLU-PP-332 reset and increased calorie intake; overlap also permitted by speaker
Limitations: No dose, frequency, duration or phase interval is given. TELLUS dosing does not supply the video’s missing protocol.
Verify exact identity and formulation before assigning O304 findings to an ATX-304 product.
Context: A 2026 phase 1b abstract was noted but full results were inaccessible.
Limitations: The older trial is not the whole development record; unknown is not zero exposure.
These compounds share an Atlas pathway label. That is a navigation connection, not evidence of equivalent effects or suitability together.
Browse this pathway in the library →Educational research summary. Study amounts are research context, not a dose recommendation. Not medical advice.